Analyst Tracker/Michael Cherny

Michael Cherny

Q: How accurate are Michael Cherny's stock ratings?

About 53% of Michael's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, measured by 13Foresight from historical prices.

Q: How is Michael ranked?

Michael Cherny is ranked #1999 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Leerink Partners

Wall Street Analyst

★★★☆☆

#1999

on 13Foresight · ranked by our own returns

51%

Success Rate

+2.3%

Average Return

18 of 35 calls profitable · -7.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 51% of Michael Cherny's ratings turned a profit when each position was held for 1 year — averaging +2.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

47 Buy 23 Hold 0 Sell

Michael's Stock Coverage 28 ratings · 2026-08-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
CAH Cardinal Health	Aug 11, 2026	BUY	Strong Buy -16.8% avg upside 29 analysts	$292.00 21.61% Upside	-2.2%	·
GDRX GoodRx Holdings	Aug 06, 2026	BUY	Buy +240.5% avg upside 28 analysts	$5.00 31.55% Upside	-1.6%	·
MEDP Medpace Holdings	Jul 23, 2026	HOLD	Buy -19.9% avg upside 17 analysts	$620.00 2.36% Upside	-1.1%	·
PGNY Progyny	Jul 22, 2026	BUY	Strong Buy +22.1% avg upside 14 analysts	$38.00 42.99% Upside	-14.1%	·
ALGN Align Tech	Jun 30, 2026	BUY	Strong Buy +71.4% avg upside 21 analysts	$230.00 32.99% Upside	+3.2%	·
CERT Certara	Jun 16, 2026	BUY	Buy +61.7% avg upside 22 analysts	$8.00 1.53% Downside	+34.4%	·
XRAY DENTSPLY SIRONA	Jun 12, 2026	HOLD	Buy +148.0% avg upside 25 analysts	—	+15.1%	·
MDLN Medline	Jun 12, 2026	BUY	Strong Buy +35.6% avg upside 27 analysts	$52.00 48.46% Upside	-7.6%	·
ICLR Icon	May 28, 2026	HOLD	Strong Buy +13.8% avg upside 26 analysts	$145.00 12.48% Downside	+22.2%	·
DOCS Doximity	May 15, 2026	BUY	Buy +32.8% avg upside 28 analysts	$25.00 4.18% Downside	+33.3%	·
HIMS Hims & Hers Health	Apr 16, 2026	HOLD	Buy -8.0% avg upside 22 analysts	—	+12.5%	·
CVS CVS Health	Mar 24, 2026	BUY	Strong Buy +12.8% avg upside 39 analysts	$98.00 4.89% Upside	+30.4%	·
HSIC Henry Schein	Feb 24, 2026	HOLD	Buy +1.9% avg upside 25 analysts	$87.00 2.35% Downside	+7.0%	·
NVST Envista Holdings	Feb 06, 2026	BUY	Buy +7.7% avg upside 19 analysts	$35.00 22.78% Upside	-3.1%	·
WAY Waystar Holding Corp.	Feb 02, 2026	BUY	Strong Buy +52.2% avg upside 30 analysts	$43.00 76.91% Upside	-7.0%	·
IQV IQVIA Holdings	Dec 14, 2025	BUY	Strong Buy -0.4% avg upside 39 analysts	$256.00 5.06% Upside	+8.1%	·
DGX Quest Diagnostics	Oct 22, 2025	BUY	Buy -22.7% avg upside 34 analysts	$210.00 11.67% Downside	+33.3%	·
ACH Accendra Health	Oct 09, 2025	HOLD	Sell +1251.6% avg upside 17 analysts	$6.00 376.29% Upside	-38.9%	·
LH Labcorp Holdings	Oct 08, 2025	BUY	Strong Buy -15.8% avg upside 37 analysts	$342.00 6.16% Upside	+16.7%	·
COR Cencora	Oct 06, 2025	BUY	Buy -3.4% avg upside 44 analysts	$361.00 8.17% Upside	+6.7%	·
MCK McKesson	Oct 06, 2025	BUY	Strong Buy -15.1% avg upside 28 analysts	—	+17.6%	·
TDOC Teladoc	Jul 30, 2025	HOLD	Buy +317.4% avg upside 38 analysts	$7.50 10.10% Upside	-11.1%	·
VRTX Vertex Pharmaceuticals	Dec 20, 2024	BUY	Strong Buy -15.5% avg upside 62 analysts	$542.00 2.41% Upside	+14.8%	·
DD DuPont de Nemours	Sep 04, 2024	HOLD	Strong Buy +2.2% avg upside 26 analysts	—	-3.6%	·
TSE:TRX Tanzanian Royalty Exploration	Jul 08, 2024	BUY	Strong Buy +123.0% avg upside 4 analysts	—	-16.4%	·
SONX Sonendo	Jul 11, 2023	BUY	Buy +1122.8% avg upside 5 analysts	$3.00 209.54% Upside	·	·
MDRX Veradigm	Jun 14, 2023	BUY	Buy +199.6% avg upside 22 analysts	$21.50 338.70% Upside	-21.6%	·
AMWL American Well	Jan 05, 2022	HOLD	Buy +9.6% avg upside 15 analysts	$7.50 42.21% Downside	-37.7%	·

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Michael Cherny — Frequently Asked Questions

How accurate are Michael Cherny's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Michael's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, or -7.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Michael ranked on 13Foresight?

Michael Cherny is currently ranked #1999 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Michael cover?

Michael most recently has ratings on CAH, GDRX, MEDP, PGNY, ALGN, CERT, XRAY, MDLN, ICLR, DOCS, HIMS, CVS and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Michael Cherny

Rating Distribution

Welcome to 13Foresight!